Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard ba...
Gespeichert in:
| Veröffentlicht in: | Cells (Basel, Switzerland) Switzerland), 2019-11, Vol.8 (11), p.1432 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | 1432 |
| container_title | Cells (Basel, Switzerland) |
| container_volume | 8 |
| creator | Mogollón, Pedro Díaz-Tejedor, Andrea Algarín, Esperanza M Paíno, Teresa Garayoa, Mercedes Ocio, Enrique M |
| description | A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse. |
| doi_str_mv | 10.3390/cells8111432 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6912619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2548333886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-9563b5fe6f670493384ee04b6682be761683579433815115721604afafc711243</originalsourceid><addsrcrecordid>eNpdkc1LAzEQxYMoVrQ3zxLw4sFqJskmuxdBi1_QImg9h3Sbranppia7Qv97U1pLdS4ZZn483uQhdArkirGCXJfGuZgDAGd0Dx1RIlmPc1Ls7_Qd1I1xRlLlIIBkh6jDQApBZXGERnfWOz-1pXb4Tpef0-DbeoJ9hV9NtLHRdWlw43G_DcHUDX5Lk4kOk7hC-joYbGs8bF1jF87g4dI4P9cn6KDSLpru5j1G7w_3o_5Tb_Dy-Ny_HfRKDrTpFZlg46wyohKS8IKxnBtD-FiInI6NFCBylsmCpwVkAJmkIAjXla5KCUA5O0Y3a91FO56bSZkMBu3UIti5DkvltVV_N7X9UFP_rUQBVECRBC42AsF_tSY2am7j6k91bXwbFWWQSyYZiISe_0Nnvg11Ok_RjOcsmcxX1OWaKoOPMZhqawaIWiWmdhNL-NnuAVv4Nx_2Aw-RkCw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548333886</pqid></control><display><type>article</type><title>Biological Background of Resistance to Current Standards of Care in Multiple Myeloma</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Mogollón, Pedro ; Díaz-Tejedor, Andrea ; Algarín, Esperanza M ; Paíno, Teresa ; Garayoa, Mercedes ; Ocio, Enrique M</creator><creatorcontrib>Mogollón, Pedro ; Díaz-Tejedor, Andrea ; Algarín, Esperanza M ; Paíno, Teresa ; Garayoa, Mercedes ; Ocio, Enrique M</creatorcontrib><description>A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse.</description><identifier>ISSN: 2073-4409</identifier><identifier>EISSN: 2073-4409</identifier><identifier>DOI: 10.3390/cells8111432</identifier><identifier>PMID: 31766279</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Bone marrow ; Cell cycle ; Cloning ; Immunomodulation ; Medical prognosis ; Monoclonal antibodies ; Multiple myeloma ; Mutation ; Plasma ; Precision medicine ; Proteasome inhibitors ; Proteins ; Review</subject><ispartof>Cells (Basel, Switzerland), 2019-11, Vol.8 (11), p.1432</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-9563b5fe6f670493384ee04b6682be761683579433815115721604afafc711243</citedby><cites>FETCH-LOGICAL-c412t-9563b5fe6f670493384ee04b6682be761683579433815115721604afafc711243</cites><orcidid>0000-0002-5765-0085 ; 0000-0002-6108-0986 ; 0000-0003-2194-2841 ; 0000-0002-0201-3572 ; 0000-0003-0802-9767</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912619/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912619/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,862,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31766279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mogollón, Pedro</creatorcontrib><creatorcontrib>Díaz-Tejedor, Andrea</creatorcontrib><creatorcontrib>Algarín, Esperanza M</creatorcontrib><creatorcontrib>Paíno, Teresa</creatorcontrib><creatorcontrib>Garayoa, Mercedes</creatorcontrib><creatorcontrib>Ocio, Enrique M</creatorcontrib><title>Biological Background of Resistance to Current Standards of Care in Multiple Myeloma</title><title>Cells (Basel, Switzerland)</title><addtitle>Cells</addtitle><description>A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse.</description><subject>Bone marrow</subject><subject>Cell cycle</subject><subject>Cloning</subject><subject>Immunomodulation</subject><subject>Medical prognosis</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Mutation</subject><subject>Plasma</subject><subject>Precision medicine</subject><subject>Proteasome inhibitors</subject><subject>Proteins</subject><subject>Review</subject><issn>2073-4409</issn><issn>2073-4409</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkc1LAzEQxYMoVrQ3zxLw4sFqJskmuxdBi1_QImg9h3Sbranppia7Qv97U1pLdS4ZZn483uQhdArkirGCXJfGuZgDAGd0Dx1RIlmPc1Ls7_Qd1I1xRlLlIIBkh6jDQApBZXGERnfWOz-1pXb4Tpef0-DbeoJ9hV9NtLHRdWlw43G_DcHUDX5Lk4kOk7hC-joYbGs8bF1jF87g4dI4P9cn6KDSLpru5j1G7w_3o_5Tb_Dy-Ny_HfRKDrTpFZlg46wyohKS8IKxnBtD-FiInI6NFCBylsmCpwVkAJmkIAjXla5KCUA5O0Y3a91FO56bSZkMBu3UIti5DkvltVV_N7X9UFP_rUQBVECRBC42AsF_tSY2am7j6k91bXwbFWWQSyYZiISe_0Nnvg11Ok_RjOcsmcxX1OWaKoOPMZhqawaIWiWmdhNL-NnuAVv4Nx_2Aw-RkCw</recordid><startdate>20191113</startdate><enddate>20191113</enddate><creator>Mogollón, Pedro</creator><creator>Díaz-Tejedor, Andrea</creator><creator>Algarín, Esperanza M</creator><creator>Paíno, Teresa</creator><creator>Garayoa, Mercedes</creator><creator>Ocio, Enrique M</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5765-0085</orcidid><orcidid>https://orcid.org/0000-0002-6108-0986</orcidid><orcidid>https://orcid.org/0000-0003-2194-2841</orcidid><orcidid>https://orcid.org/0000-0002-0201-3572</orcidid><orcidid>https://orcid.org/0000-0003-0802-9767</orcidid></search><sort><creationdate>20191113</creationdate><title>Biological Background of Resistance to Current Standards of Care in Multiple Myeloma</title><author>Mogollón, Pedro ; Díaz-Tejedor, Andrea ; Algarín, Esperanza M ; Paíno, Teresa ; Garayoa, Mercedes ; Ocio, Enrique M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-9563b5fe6f670493384ee04b6682be761683579433815115721604afafc711243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bone marrow</topic><topic>Cell cycle</topic><topic>Cloning</topic><topic>Immunomodulation</topic><topic>Medical prognosis</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Mutation</topic><topic>Plasma</topic><topic>Precision medicine</topic><topic>Proteasome inhibitors</topic><topic>Proteins</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mogollón, Pedro</creatorcontrib><creatorcontrib>Díaz-Tejedor, Andrea</creatorcontrib><creatorcontrib>Algarín, Esperanza M</creatorcontrib><creatorcontrib>Paíno, Teresa</creatorcontrib><creatorcontrib>Garayoa, Mercedes</creatorcontrib><creatorcontrib>Ocio, Enrique M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cells (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mogollón, Pedro</au><au>Díaz-Tejedor, Andrea</au><au>Algarín, Esperanza M</au><au>Paíno, Teresa</au><au>Garayoa, Mercedes</au><au>Ocio, Enrique M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biological Background of Resistance to Current Standards of Care in Multiple Myeloma</atitle><jtitle>Cells (Basel, Switzerland)</jtitle><addtitle>Cells</addtitle><date>2019-11-13</date><risdate>2019</risdate><volume>8</volume><issue>11</issue><spage>1432</spage><pages>1432-</pages><issn>2073-4409</issn><eissn>2073-4409</eissn><abstract>A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31766279</pmid><doi>10.3390/cells8111432</doi><orcidid>https://orcid.org/0000-0002-5765-0085</orcidid><orcidid>https://orcid.org/0000-0002-6108-0986</orcidid><orcidid>https://orcid.org/0000-0003-2194-2841</orcidid><orcidid>https://orcid.org/0000-0002-0201-3572</orcidid><orcidid>https://orcid.org/0000-0003-0802-9767</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2073-4409 |
| ispartof | Cells (Basel, Switzerland), 2019-11, Vol.8 (11), p.1432 |
| issn | 2073-4409 2073-4409 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6912619 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Bone marrow Cell cycle Cloning Immunomodulation Medical prognosis Monoclonal antibodies Multiple myeloma Mutation Plasma Precision medicine Proteasome inhibitors Proteins Review |
| title | Biological Background of Resistance to Current Standards of Care in Multiple Myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A23%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biological%20Background%20of%20Resistance%20to%20Current%20Standards%20of%20Care%20in%20Multiple%20Myeloma&rft.jtitle=Cells%20(Basel,%20Switzerland)&rft.au=Mogoll%C3%B3n,%20Pedro&rft.date=2019-11-13&rft.volume=8&rft.issue=11&rft.spage=1432&rft.pages=1432-&rft.issn=2073-4409&rft.eissn=2073-4409&rft_id=info:doi/10.3390/cells8111432&rft_dat=%3Cproquest_pubme%3E2548333886%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548333886&rft_id=info:pmid/31766279&rfr_iscdi=true |